Showing results (2341-2350 of 3,353) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|May 1, 2012
Pharmacoeconomics of the myeloid growth factors: a critical and systematic reviewBradford R Hirsch, Gary H LymanPharmacoeconomics|May 20, 2018
Are PCSK9 Inhibitors Cost Effective?Max J Korman, Kjetil Retterstøl, Ivar Sønbø Kristiansen, et al.Pharmacoeconomics|April 28, 2018
Does Non-Adherence Increase Treatment Costs in Schizophrenia?Mark Pennington, Paul McCronePharmacoeconomics|April 4, 2002
Optimising drug utilisation in long term careKate L Lapane, Carmel M HughesPharmacoeconomics|April 4, 2002
Acute exacerbations of chronic bronchitis: a pharmacoeconomic review of antibacterial useStephen Morris, Pippa Anderson, Debra E IrwinPharmacoeconomics|July 27, 2018
Cost Effectiveness of Intra-Articular Hyaluronic Acid and Disease-Modifying Drugs in Knee OsteoarthritisJean-Hugues Salmon, Anne-Christine Rat, Isabelle Charlot-Lambrecht, et al.Pharmacoeconomics|July 22, 2018
Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalDaniel Gallacher, Xavier Armoiry, Peter Auguste, et al.Pharmacoeconomics|August 24, 2018
Health State Utilities for Acute Myeloid Leukaemia: A Time Trade-off StudyNamita Joshi, Marja Hensen, Sachin Patel, et al.Pharmacoeconomics|September 9, 2018
Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalNasuh C Büyükkaramikli, Saskia de Groot, Rob Riemsma, et al.Pharmacoeconomics|September 9, 2018
Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with HyperkalemiaMark Bounthavong, Javed Butler, Chantal M Dolan, et al.Pageof 336